Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Osteosarcoma 1Lymphoma, T-Cell, Peripheral 1Esophageal Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 4Carboplatin 2viscum album peptide 1sugemalimab 1rilotumumab 1ganitumab 1endostar protein 1Zoledronic Acid 1Valacyclovir 1Thiostrepton 1Surgical Procedures, Operative 1Paclitaxel 1N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea 1Etoposide 1Darbepoetin alfa 1Cetuximab 1Catheters, Indwelling 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pleural Effusion, Malignant × endostar protein × Clear all
NCT01327235 2014-08-01

Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 2 Completed
336 enrolled
Thoracic

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡